201 related articles for article (PubMed ID: 9750028)
1. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
Sugiyama Y; Kato Y; Chu X
Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
[TBL] [Abstract][Full Text] [Related]
2. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
Chu XY; Kato Y; Niinuma K; Sudo KI; Hakusui H; Sugiyama Y
J Pharmacol Exp Ther; 1997 Apr; 281(1):304-14. PubMed ID: 9103511
[TBL] [Abstract][Full Text] [Related]
3. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
Chu XY; Kato Y; Sugiyama Y
Cancer Res; 1997 May; 57(10):1934-8. PubMed ID: 9157988
[TBL] [Abstract][Full Text] [Related]
4. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
[TBL] [Abstract][Full Text] [Related]
5. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
Chu XY; Kato Y; Ueda K; Suzuki H; Niinuma K; Tyson CA; Weizer V; Dabbs JE; Froehlich R; Green CE; Sugiyama Y
Cancer Res; 1998 Nov; 58(22):5137-43. PubMed ID: 9823324
[TBL] [Abstract][Full Text] [Related]
6. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats.
Chu XY; Kato Y; Sugiyama Y
Drug Metab Dispos; 1999 Apr; 27(4):440-1. PubMed ID: 10101137
[TBL] [Abstract][Full Text] [Related]
7. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
[TBL] [Abstract][Full Text] [Related]
8. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
9. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
[TBL] [Abstract][Full Text] [Related]
10. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
[TBL] [Abstract][Full Text] [Related]
11. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione.
Paulusma CC; van Geer MA; Evers R; Heijn M; Ottenhoff R; Borst P; Oude Elferink RP
Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):393-401. PubMed ID: 10024515
[TBL] [Abstract][Full Text] [Related]
12. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
Iyer L; Ramírez J; Shepard DR; Bingham CM; Hossfeld DK; Ratain MJ; Mayer U
Cancer Chemother Pharmacol; 2002 Apr; 49(4):336-41. PubMed ID: 11914914
[TBL] [Abstract][Full Text] [Related]
13. Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
Sasabe H; Tsuji A; Sugiyama Y
J Pharmacol Exp Ther; 1998 Mar; 284(3):1033-9. PubMed ID: 9495864
[TBL] [Abstract][Full Text] [Related]
14. Modulation of liver canalicular transport processes by the tyrosine-kinase inhibitor genistein: implications of genistein metabolism in the rat.
Jäger W; Winter O; Halper B; Salamon A; Sartori M; Gajdzik L; Hamilton G; Theyer G; Graf J; Thalhammer T
Hepatology; 1997 Dec; 26(6):1467-76. PubMed ID: 9397986
[TBL] [Abstract][Full Text] [Related]
15. Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2.
Morikawa A; Goto Y; Suzuki H; Hirohashi T; Sugiyama Y
Pharm Res; 2000 May; 17(5):546-52. PubMed ID: 10888306
[TBL] [Abstract][Full Text] [Related]
16. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H
Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871
[TBL] [Abstract][Full Text] [Related]
17. An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells.
Chen ZS; Sumizawa T; Furukawa T; Ono K; Tani A; Komatsu M; Akiyama S
Cancer Lett; 1999 Apr; 138(1-2):13-22. PubMed ID: 10378768
[TBL] [Abstract][Full Text] [Related]
18. Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats.
Wang X; Rao Z; Qin H; Zhang G; Ma Y; Jin Y; Han M; Shi A; Wang Y; Wu X
Biopharm Drug Dispos; 2016 Oct; 37(7):421-432. PubMed ID: 27510985
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of xenobiotic detoxification system mediated by efflux transporters].
Suzuki H
Yakugaku Zasshi; 1999 Nov; 119(11):822-34. PubMed ID: 10590710
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen RH; van Alphen RJ; Verweij J; Loos WJ; Nooter K; Stoter G; Sparreboom A
Clin Cancer Res; 2001 Aug; 7(8):2182-94. PubMed ID: 11489791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
